January 30, 2018, 7:00 AM Mountain Daylight Time – Belgrade, MT

Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) is providing this default status report in accordance with National Policy 12-203 – Management Cease Trade Orders. The Company’s audited annual financial statements, related management’s discussion and analysis and accompanying CEO and CFO certifications for the financial year ended September 30, 2017 (collectively, the “Required Filings”) would not be completed by the prescribed period for the filing of such documents under Parts 4 and 5 of National Instrument 51-102 respecting Continuous Disclosure Obligations and pursuant to National Instrument 52-109 respecting Certification of Disclosure in Issuer’s Annual and Interim Filings, being September 30th, 2017.

Due to cash flow constraints related to the collection of receivables, specifically a change in business focus to the personal injury market which requires additional time for settlement and subsequent collection, the Company requires more time to complete its financial statements and has requested an extension of the required filings.

As a result of this delay in the filing of the Required Filings, the British Columbia Securities Commission granted a management cease trade order (the “MCTO”) on January 30th, 2018 against the Company’s Chief Executive Officer and Chief Financial Officer, rather than a general cease trade order against the Company. The MCTO restricts all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company until such time as the Required Filings have been filed by the Company. The MCTO does not generally affect the ability of shareholders who are not insiders of the Company to trade their securities.

The Company expects it will file the Required Filings by April 3, 2018. The audit process is underway and the Company is working closely with its auditors and expects to complete the remaining steps in order to file the Required Filings as soon as possible.

The Company intends to satisfy the provisions of the alternative information guidelines set out in sections 4.3 and 4.4 of National Policy 12-203 Management Cease Trade Orders by issuing bi-weekly default status reports in the form of further news releases, which will be filed on SEDAR, until the Required Filings have been filed.

The Company confirms as of the date of this news release that there is no insolvency proceeding against it and there is no other material information concerning the affairs of the Company that has not been generally disclosed. The Company would file, to the extent applicable, its next default status report on or about February 13, 2018.

Lattice Biologics Ltd.
Guy Cook,
Chief Executive Officer
Telephone No: (480) 563-0800


Subscribe to Lattice News Updates
Follow us on Twitter: @LatticeBio
PDF Download Download a PDF copy of this Press Release

Media Contact:
Lattice Biologics Ltd.
512 E Madison Ave, Suite #101
Belgrade, MT 59714
480-563-0800 Office